REPATHA is indicated: To reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol -lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia , to reduce LDL-C As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C As an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia , to reduce LDL-C REPATHA is a PCSK9 inhibitor indicated: To reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease as an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol -lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia , to reduce LDL-C as an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C as an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia , to reduce LDL-C